Neurogene — Down 36% — Extends Losses After Side Effect Derails Its Rett Syndrome Drug The company is now scrapping a high dose of its Rett syndrome drug after a patient experienced a serious side effect.
Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?" Neurogene has been on a huge run in 2024. That came to a halt after the company released trial results. But, the results may be better than the market thinks.
Neurogene Stock Tanks After Adverse Event In Early-Stage Rett Syndrome Gene Therapy Trial Neurogene reports interim Phase 1/2 trial results for NGN-401 gene therapy in treating pediatric Rett syndrome, showing improved safety and efficacy.
NGNE Stock Earnings: Neurogene Misses EPS for Q2 2024 NGNE stock results show that Neurogene missed analyst estimates for earnings per share the second quarter of 2024.
NGNE Stock Earnings: Neurogene Beats EPS for Q1 2024 NGNE stock results show that Neurogene beat analyst estimates for earnings per share the first quarter of 2024.
